Aker BioMarine will release its Q3 2021 results on Friday 29 October 2021 at 07:00 am CEST.
At 09:00 CEST on the same day, the management will host a conference call to present the results. Following the presentation, there will be a Q&A session, where written questions can be submitted over the Teams Live Event.
The webcasted presentation will be in English. To join, please use the following link:
https://teams.microsoft.com/l/meetup-join/19%3ameeting_MDEyYzkyNjgtYjlmYi00MTQ2LTljZTAtYmZlOTg5MWVhMjYy%40thread.v2/0?context=%7b%22Tid%22%3a%22f3733015-082c-4aa6-8823-36db9bfdc6ba%22%2c%22Oid%22%3a%2276bab8a9-cee6-4245-ade2-eb08f5723da4%22%2c%22IsBroadcastMeeting%22%3atrue%7d&btype=a&role=a
A link to the presentation will also be available at www.akerbiomarine.com/investor. A replay of the presentation and Q&A session, in addition to the quarterly report and presentation material, will be made available soon after the presentation at the same web address.
For further information, please contact
Carl Christian Bachke, Head of Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.